Skip to main content

Table 1 Patients enrolled in the CENTAURO-2 phase Ib clinical trial

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Characteristic

n

Percent

Age

  ≥ 50

38

76%

  < 50

12

24%

Sex

 Female

33

66%

 Male

17

34%

Primary tumor sitea

 Breast

11

22%

 Colon

8

16%

 Lung

7

14%

 Ovary

7

14%

 Kidney

3

6%

 Uterus

3

6%

 Soft tissues

3

6%

 Anal canal

2

4%

 Rectum

2

4%

 Others

4

8%

Metastasisb

 Liver

13

27%

 Lung

8

16%

 Bone

6

12%

 Lymph nodes

6

12%

 Suprarenal glands

4

8%

 Soft tissue

2

4%

 Others

9

16%

 Without metastasis

2

4%

Statusc

 PD

37

74%

 SD

13

26%

ECOG PS

 0

8

16%

 1

34

68%

 2

8

16%

Trial vaccinations

 Completedd

41

82%

 No completed

9

18%

  1. Patients were eligible for enrollment after having received available therapy and were no longer responding. ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; SD, stable disease. aat the time of initial diagnosis; bat the time of trial inclusion; cRECIST classification at the time of trial inclusion; d39 patients of the 41 were available for antibody tests and sVEGFR-2 at week thirteen; 38 patients were available for platelet VEGF
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us